📊 BBLGW Key Takeaways
Is Bone Biologics Corp (BBLGW) a Good Investment?
Bone Biologics is a pre-revenue or near-complete revenue collapse company with zero gross profit, massive operating losses, and severely negative cash flow generation. The company is rapidly burning through its cash reserves ($5.3M) at approximately $2.7M annually with no clear path to profitability or sustainable operations.
Bone Biologics Corp shows extremely weak fundamentals, with essentially no revenue, zero gross profit, and continued multi-million-dollar operating and net losses. While the balance sheet is currently clean and cash-heavy with no long-term debt, the business remains dependent on cash reserves rather than operating performance, making growth quality and long-term sustainability very poor.
Why Buy Bone Biologics Corp Stock? BBLGW Key Strengths
- Strong liquidity position with $5.3M cash and 13.85x current ratio
- Minimal debt burden with zero long-term debt provides financial flexibility
- Positive stockholders equity of $5.4M and conservative capital structure
- Strong liquidity with $5.33M in cash and a 13.85x current ratio
- No long-term debt and very low balance sheet leverage
- Positive equity base of $5.38M provides near-term financial flexibility
BBLGW Stock Risks: Bone Biologics Corp Investment Risks
- Operating cash flow of -$2.7M annually indicates cash will deplete in ~2 years at current burn rate
- Complete revenue collapse (100% YoY decline) suggests business model failure or operational discontinuation
- Negative operating margin of -1,268,604% demonstrates inability to achieve profitability with current revenue base
- Dilution risk evident from worsening EPS despite net income improvement, indicating significant equity issuance
- No gross profit generation suggests fundamental product viability or market demand issues
- Revenue has effectively disappeared, indicating no meaningful commercial traction
- Persistent negative operating cash flow and free cash flow are steadily consuming cash reserves
- Profitability metrics are extremely weak, showing the company is far from self-sustaining
Key Metrics to Watch
- Operating cash flow trend and cash runway remaining
- Revenue stabilization or return to meaningful sales levels
- Gross margin recovery once revenue reaches viable levels
- Additional equity dilution and insider activity patterns
- Quarterly revenue progression and evidence of sustained commercialization
- Operating cash burn relative to cash and equivalents
Bone Biologics Corp (BBLGW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.85x current ratio provides a solid financial cushion.
BBLGW Profit Margin, ROE & Profitability Analysis
BBLGW vs Healthcare Sector: How Bone Biologics Corp Compares
How Bone Biologics Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bone Biologics Corp Stock Overvalued? BBLGW Valuation Analysis 2026
Based on fundamental analysis, Bone Biologics Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bone Biologics Corp Balance Sheet: BBLGW Debt, Cash & Liquidity
BBLGW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bone Biologics Corp's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-28.96 indicates the company is currently unprofitable.
BBLGW Revenue Growth, EPS Growth & YoY Performance
BBLGW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2021 | $1.1B | -$380.0K | N/A |
| Q1 2021 | $1.1B | -$431.7K | N/A |
| Q3 2020 | $1.1B | -$380.0K | N/A |
| Q2 2020 | $1.1B | -$380.0K | N/A |
| Q1 2020 | $1.1B | -$596.9K | N/A |
| Q1 2019 | $1.1B | -$1.4M | N/A |
| Q3 2018 | $1.1B | -$241.7K | N/A |
| Q2 2018 | $1.1B | $1.0M | $0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bone Biologics Corp Dividends, Buybacks & Capital Allocation
BBLGW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bone Biologics Corp (CIK: 0001419554)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BBLGW
What is the AI rating for BBLGW?
Bone Biologics Corp (BBLGW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BBLGW's key strengths?
Claude: Strong liquidity position with $5.3M cash and 13.85x current ratio. Minimal debt burden with zero long-term debt provides financial flexibility. ChatGPT: Strong liquidity with $5.33M in cash and a 13.85x current ratio. No long-term debt and very low balance sheet leverage.
What are the risks of investing in BBLGW?
Claude: Operating cash flow of -$2.7M annually indicates cash will deplete in ~2 years at current burn rate. Complete revenue collapse (100% YoY decline) suggests business model failure or operational discontinuation. ChatGPT: Revenue has effectively disappeared, indicating no meaningful commercial traction. Persistent negative operating cash flow and free cash flow are steadily consuming cash reserves.
What is BBLGW's revenue and growth?
Bone Biologics Corp reported revenue of $255.0.
Does BBLGW pay dividends?
Bone Biologics Corp does not currently pay dividends.
Where can I find BBLGW SEC filings?
Official SEC filings for Bone Biologics Corp (CIK: 0001419554) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BBLGW's EPS?
Bone Biologics Corp has a diluted EPS of $-2.65.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BBLGW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bone Biologics Corp has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BBLGW stock overvalued or undervalued?
Valuation metrics for BBLGW: ROE of -57.8% (sector avg: 15%), net margin of -1,219,212.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BBLGW stock in 2026?
Our dual AI analysis gives Bone Biologics Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BBLGW's free cash flow?
Bone Biologics Corp's operating cash flow is $-2.7M, with capital expenditures of $504.0. FCF margin is -1,055,550.6%.
How does BBLGW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,219,212.2% (avg: 12%), ROE -57.8% (avg: 15%), current ratio 13.85 (avg: 2).